TY - JOUR T1 - Response to Tocilizumab in Rheumatoid Arthritis Is Not Influenced by the Body Mass Index of the Patient JF - The Journal of Rheumatology JO - J Rheumatol SP - 580 LP - 584 DO - 10.3899/jrheum.140673 VL - 42 IS - 4 AU - Yves-Marie Pers AU - Marie Godfrin-Valnet AU - Joseph Lambert AU - Clémentine Fortunet AU - Elodie Constant AU - Thibault Mura AU - Béatrice Pallot-Prades AU - Christian Jorgensen AU - Jean-Francis Maillefert AU - Hubert Marotte AU - Daniel Wendling AU - Philippe Gaudin Y1 - 2015/04/01 UR - http://www.jrheum.org/content/42/4/580.abstract N2 - Objective. To assess the relationship between the body mass index (BMI) and the efficacy of tocilizumab (TCZ) in patients with rheumatoid arthritis (RA). Methods. We conducted a retrospective study in 222 patients with RA followed by 5 centers. The European League Against Rheumatism response was evaluated at 6 months. Univariate and multivariate logistic regressions were performed. Results. No significant association between the BMI and the response to TCZ at 6 months was found after adjustment for potential confounding factors (adjusted OR 0.45, 95% CI 0.16–1.24, p = 0.13 and OR 1.19, 95% CI 0.31–4.48, p = 0.78 for BMI 25–30 kg/m2 and BMI > 30 kg/m2, respectively, compared to BMI < 25 kg/m2). Conclusion. Response to TCZ in patients with RA is not influenced by the baseline BMI, in contrast to anti-tumor necrosis factor drugs. ER -